Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | galactosyltransferase | 0.0226 | 1 | 1 |
Echinococcus granulosus | cAMP specific 3'5' cyclic phosphodiesterase | 0.0184 | 0.7484 | 0.7484 |
Brugia malayi | Probable 3',5'-cyclic phosphodiesterase R153.1, putative | 0.0161 | 0.6139 | 0.6139 |
Echinococcus granulosus | Metazoa galactosyltransferase | 0.0226 | 1 | 1 |
Echinococcus multilocularis | cAMP specific 3',5' cyclic phosphodiesterase | 0.0161 | 0.6139 | 0.6139 |
Giardia lamblia | CAMP-specific 3,5-cyclic phosphodiesterase 4B | 0.0184 | 0.7484 | 0.5 |
Echinococcus multilocularis | Metazoa galactosyltransferase | 0.0191 | 0.7898 | 0.7898 |
Echinococcus granulosus | Ribosomal protein L34a | 0.0166 | 0.6438 | 0.6438 |
Loa Loa (eye worm) | cyclic AMP specific phosphodiesterase PDE4D5A | 0.0161 | 0.6139 | 0.6139 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0211 | 0.9126 | 0.5 |
Echinococcus granulosus | cAMP specific 3'5' cyclic phosphodiesterase | 0.0184 | 0.7484 | 0.7484 |
Echinococcus multilocularis | cAMP specific 3',5' cyclic phosphodiesterase | 0.0184 | 0.7484 | 0.7484 |
Schistosoma mansoni | camp-specific 35-cyclic phosphodiesterase | 0.0184 | 0.7484 | 0.7484 |
Echinococcus multilocularis | Metazoa galactosyltransferase | 0.0226 | 1 | 1 |
Echinococcus multilocularis | Ribosomal protein L34a | 0.0166 | 0.6438 | 0.6438 |
Echinococcus granulosus | cAMP specific 3'5' cyclic phosphodiesterase | 0.0161 | 0.6139 | 0.6139 |
Loa Loa (eye worm) | hypothetical protein | 0.0184 | 0.7484 | 0.7484 |
Echinococcus multilocularis | cAMP specific 3',5' cyclic phosphodiesterase | 0.0184 | 0.7484 | 0.7484 |
Schistosoma mansoni | beta-14-galactosyltransferase | 0.0226 | 1 | 1 |
Schistosoma mansoni | beta-14-galactosyltransferase | 0.0226 | 1 | 1 |
Toxoplasma gondii | 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein | 0.0184 | 0.7484 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.